Locus ceruleus degeneration is ubiquitous in Alzheimer’s disease: Possible implications for diagnosis and treatment
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Degeneration of the locus ceruleus (LC) and decreased cortical levels of norepinephrine are common findings in Alzheimer’s disease (AD), but their significance is unknown. Because the noradrenergic system is accessible to pharmacological intervention, the role of LC degeneration and noradrenergic dysfunction in the pathogenesis and clinical manifestations of AD needs clarification. Hypothetically, loss of noradrenergic innervation could cause microvascular dysfunction and manifest as ischemia. The objectives of this study were to develop a scale for assessment of LC degeneration and to determine whether degeneration of the LC correlates quantitatively with either duration of clinical dementia, overall severity of AD pathology or with measures of ischemic non‐focal white matter disease (WMD) in AD. This report is a pathological follow‐up of a clinical longitudinal dementia study of 66 consecutive cases of AD without admixture of vascular dementia (VaD) from the Lund Longitudinal Dementia Study, neuropathologically diagnosed between 1990 and 1999. Ten cases of VaD were included for comparative purposes. No correlation between degree of LC degeneration and duration of dementia, AD or WMD severity was found. LC degeneration was significantly more severe in the AD group than in the VaD group. Even though LC degeneration was not associated with WMD or the severity of AD pathology in this AD material, we suggest that clinical studies on the consequences of noradrenergic dysfunction are warranted. Treatment augmenting noradrenergic signaling is available and safe. The marked difference in the level of LC degeneration between AD and VaD cases suggests that LC degeneration could be used as a diagnostic marker of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Alzheimer's Disease and Senile Dementia: Loss of Neurons in the Basal Forebrain
Whitehouse, P., Price, D., Struble, R., Clark, A., Coyle, J., & DeLong, M. R. (1982) · Science · doi:10.1126/science.7058341 · Cited by 3,627 · cited 7×
“Historically, researchers have focused primarily on damage to the cholinergic system, a well-known finding in AD.(1,2) Degeneration of the nucleus basalis Meynert (NBM) is common in AD, but it is not the only nerve cell nucleus affected in this disease.”
BackgroundInfluentialSubacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization
Orgogozo, J.-M., Gilman, S., Dartigues, J.-F., Laurent, B., Puel, M., Kirby, L. C., Jouanny, P., Dubois, B., Eisner, L., Flitman, S., et al. (2003) · Neurology · doi:10.1212/01.wnl.0000073623.84147.a8 · Cited by 1,356 · cited 1×
“Positive results of such therapy on the symptomatology or progression of AD would provide near irrefutable evidence of a role for noradrenergic dysfunction in AD, as well as open up a new therapeutic avenue without the potential risks associated with A-beta-targeting treatment.(30,31)”
BackgroundA white matter disorder in dementia of the Alzheimer type: A pathoanatomical study
Brun, A., & Englund, E. (1986) · Annals of Neurology · doi:10.1002/ana.410190306 · Cited by 1,014
Self-citationThe neuropathology of aminergic nuclei in Alzheimer's disease
Zweig, R. M., Ross, C. A., Hedreen, J. C., Steele, C., Cardillo, J. E., Whitehouse, P. J., Folstein, M. F., & Price, D. L. (1988) · Annals of Neurology · doi:10.1002/ana.410240210 · Cited by 446
Neuron loss in key cholinergic and aminergic nuclei in Alzheimer disease: a meta-analysis
Lyness, S. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00057-x · Cited by 240 · cited 1×
“Degeneration of the nucleus basalis Meynert (NBM) is common in AD, but it is not the only nerve cell nucleus affected in this disease.(3) Reportedly, the locus ceruleus (LC) – the center of noradrenergic neurons projecting to the cortex and gray subcortical areas – undergoes even more severe degeneration in AD than do…”
BackgroundNEURONAL DEGENERATION IN LOCUS CERULEUS AND CORTICAL CORRELATES OF ALZHEIMER DISEASE
Bondareff, W., Mountjoy, C. Q., Roth, M., Rossor, M. N., Iversen, L. L., Reynolds, G. P., & Hauser, D. L. (1987) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-198701040-00005 · Cited by 166
Cited by
Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years
Braak, H., Thal, D. R., Ghebremedhin, E., & Del Tredici, K. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318232a379 · Cited by 2,194
The pathological process underlying Alzheimer’s disease in individuals under thirty
Braak, H., & Del Tredici, K. (2011) · Acta Neuropathologica · doi:10.1007/s00401-010-0789-4 · Cited by 812
The preclinical phase of the pathological process underlying sporadic Alzheimer’s disease
Braak, H., & Del Tredici, K. (2015) · Brain · doi:10.1093/brain/awv236 · Cited by 540
“…1992; Busch et al., 1997; Sassin et al., 2000; Parvizi et al., 2001; Lyness et al., 2003; Marien et al., 2004; Mesulam, 2004, Mesulam et al., 2004; Haglund et al., 2006; Grudzien et al., 2007; Weinshenker, 2008; Benarroch, 2009; Grinberg et al., 2009; Sara, 2009; Simic et al., 2009; Braak and…”
Alzheimer’s pathogenesis: is there neuron-to-neuron propagation?
Braak, H., & Del Tredici, K. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0825-z · Cited by 359
Benarroch, E. E. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c2937c · Cited by 317
Metadata
- Authors
- Haglund, M., Sjöbeck, M., & Englund, E.
- Venue
- Neuropathology
- Publisher
- Wiley
- Published
- 2006-11-24
- Volume
- 26
- Issue
- 6
- Pages
- 528-532
- ISSN
- 0919-6544 (ISSN-L)
- 1440-1789
- OpenAlex
- W2113255398
- Cited by
- 81
- References
- 7
- FWCI
- 2.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.